Cargando…

Circulating miR-122 and miR-200a as biomarkers for fatal liver disease in ART-treated, HIV-1-infected individuals

Liver disease is one of the main contributors to the increased levels of morbidity and mortality seen in the HIV-1-infected, ART-treated population. Circulating miRNAs, particularly those located inside extracellular vesicles, are seen as promising biomarkers for a number of human disease conditions...

Descripción completa

Detalles Bibliográficos
Autores principales: Murray, Daniel D., Suzuki, Kazuo, Law, Matthew, Trebicka, Jonel, Neuhaus Nordwall, Jacquie, Johnson, Margaret, Vjecha, Michael J., Kelleher, Anthony D., Emery, Sean
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5589757/
https://www.ncbi.nlm.nih.gov/pubmed/28883647
http://dx.doi.org/10.1038/s41598-017-11405-8
_version_ 1783262398515249152
author Murray, Daniel D.
Suzuki, Kazuo
Law, Matthew
Trebicka, Jonel
Neuhaus Nordwall, Jacquie
Johnson, Margaret
Vjecha, Michael J.
Kelleher, Anthony D.
Emery, Sean
author_facet Murray, Daniel D.
Suzuki, Kazuo
Law, Matthew
Trebicka, Jonel
Neuhaus Nordwall, Jacquie
Johnson, Margaret
Vjecha, Michael J.
Kelleher, Anthony D.
Emery, Sean
author_sort Murray, Daniel D.
collection PubMed
description Liver disease is one of the main contributors to the increased levels of morbidity and mortality seen in the HIV-1-infected, ART-treated population. Circulating miRNAs, particularly those located inside extracellular vesicles, are seen as promising biomarkers for a number of human disease conditions, including liver-related diseases. Here, we show that serum levels of miR-122 and miR-200a are greater in HIV/HCV co-infected individuals compared to HIV-1 mono-infected individuals. We also show that miR-122 and miR-200a are elevated in ART-treated, HIV-1-infected individuals prior to the development of fatal liver disease, suggesting that these miRNA may have some potential clinical utility as biomarkers. While this study is hypothesis generating, it shows clearly that both miR-122 and miR-200a are promising novel biomarkers for liver disease in the ART-treated, HIV-1-infected population.
format Online
Article
Text
id pubmed-5589757
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-55897572017-09-13 Circulating miR-122 and miR-200a as biomarkers for fatal liver disease in ART-treated, HIV-1-infected individuals Murray, Daniel D. Suzuki, Kazuo Law, Matthew Trebicka, Jonel Neuhaus Nordwall, Jacquie Johnson, Margaret Vjecha, Michael J. Kelleher, Anthony D. Emery, Sean Sci Rep Article Liver disease is one of the main contributors to the increased levels of morbidity and mortality seen in the HIV-1-infected, ART-treated population. Circulating miRNAs, particularly those located inside extracellular vesicles, are seen as promising biomarkers for a number of human disease conditions, including liver-related diseases. Here, we show that serum levels of miR-122 and miR-200a are greater in HIV/HCV co-infected individuals compared to HIV-1 mono-infected individuals. We also show that miR-122 and miR-200a are elevated in ART-treated, HIV-1-infected individuals prior to the development of fatal liver disease, suggesting that these miRNA may have some potential clinical utility as biomarkers. While this study is hypothesis generating, it shows clearly that both miR-122 and miR-200a are promising novel biomarkers for liver disease in the ART-treated, HIV-1-infected population. Nature Publishing Group UK 2017-09-07 /pmc/articles/PMC5589757/ /pubmed/28883647 http://dx.doi.org/10.1038/s41598-017-11405-8 Text en © The Author(s) 2017 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Murray, Daniel D.
Suzuki, Kazuo
Law, Matthew
Trebicka, Jonel
Neuhaus Nordwall, Jacquie
Johnson, Margaret
Vjecha, Michael J.
Kelleher, Anthony D.
Emery, Sean
Circulating miR-122 and miR-200a as biomarkers for fatal liver disease in ART-treated, HIV-1-infected individuals
title Circulating miR-122 and miR-200a as biomarkers for fatal liver disease in ART-treated, HIV-1-infected individuals
title_full Circulating miR-122 and miR-200a as biomarkers for fatal liver disease in ART-treated, HIV-1-infected individuals
title_fullStr Circulating miR-122 and miR-200a as biomarkers for fatal liver disease in ART-treated, HIV-1-infected individuals
title_full_unstemmed Circulating miR-122 and miR-200a as biomarkers for fatal liver disease in ART-treated, HIV-1-infected individuals
title_short Circulating miR-122 and miR-200a as biomarkers for fatal liver disease in ART-treated, HIV-1-infected individuals
title_sort circulating mir-122 and mir-200a as biomarkers for fatal liver disease in art-treated, hiv-1-infected individuals
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5589757/
https://www.ncbi.nlm.nih.gov/pubmed/28883647
http://dx.doi.org/10.1038/s41598-017-11405-8
work_keys_str_mv AT murraydanield circulatingmir122andmir200aasbiomarkersforfatalliverdiseaseinarttreatedhiv1infectedindividuals
AT suzukikazuo circulatingmir122andmir200aasbiomarkersforfatalliverdiseaseinarttreatedhiv1infectedindividuals
AT lawmatthew circulatingmir122andmir200aasbiomarkersforfatalliverdiseaseinarttreatedhiv1infectedindividuals
AT trebickajonel circulatingmir122andmir200aasbiomarkersforfatalliverdiseaseinarttreatedhiv1infectedindividuals
AT neuhausnordwalljacquie circulatingmir122andmir200aasbiomarkersforfatalliverdiseaseinarttreatedhiv1infectedindividuals
AT johnsonmargaret circulatingmir122andmir200aasbiomarkersforfatalliverdiseaseinarttreatedhiv1infectedindividuals
AT vjechamichaelj circulatingmir122andmir200aasbiomarkersforfatalliverdiseaseinarttreatedhiv1infectedindividuals
AT kelleheranthonyd circulatingmir122andmir200aasbiomarkersforfatalliverdiseaseinarttreatedhiv1infectedindividuals
AT emerysean circulatingmir122andmir200aasbiomarkersforfatalliverdiseaseinarttreatedhiv1infectedindividuals